1/15
10:00 am
lenz
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
1/14
09:12 am
lenz
LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign [Yahoo! Finance]
High
Report
LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign [Yahoo! Finance]
1/14
08:30 am
lenz
LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign
High
Report
LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign
1/14
08:30 am
lenz
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
High
Report
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
1/13
04:39 pm
lenz
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
High
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
1/11
07:40 pm
lenz
LENZ Therapeutics (LENZ) Is Down 7.1% After VIZZ Middle East Deal And Early Launch Data - Has The Bull Case Changed? [Yahoo! Finance]
Medium
Report
LENZ Therapeutics (LENZ) Is Down 7.1% After VIZZ Middle East Deal And Early Launch Data - Has The Bull Case Changed? [Yahoo! Finance]
1/8
10:00 am
lenz
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
1/7
05:08 pm
lenz
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
Medium
Report
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
1/6
11:44 am
lenz
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
1/6
08:46 am
lenz
Lenz, Lunatus announce exclusive partnership for VIZZ in Middle East [Yahoo! Finance]
Low
Report
Lenz, Lunatus announce exclusive partnership for VIZZ in Middle East [Yahoo! Finance]
1/5
08:06 am
lenz
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East [Yahoo! Finance]
Low
Report
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East [Yahoo! Finance]
1/5
08:00 am
lenz
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
Medium
Report
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
1/1
10:00 am
lenz
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
12/30
12:45 pm
lenz
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
12/17
09:08 am
lenz
LENZ Therapeutics: Was That A Market Overreaction? [Seeking Alpha]
Medium
Report
LENZ Therapeutics: Was That A Market Overreaction? [Seeking Alpha]
12/15
07:20 am
lenz
LENZ Therapeutics (NASDAQ:LENZ) had its "buy" rating reaffirmed by analysts at HC Wainwright.
High
Report
LENZ Therapeutics (NASDAQ:LENZ) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/1
08:30 am
lenz
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
Low
Report
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
11/25
04:56 pm
lenz
LENZ Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
LENZ Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]
11/25
04:05 pm
lenz
LENZ Therapeutics to Present at Upcoming Investor Conferences
Low
Report
LENZ Therapeutics to Present at Upcoming Investor Conferences
11/22
07:57 am
lenz
LENZ Therapeutics (NASDAQ:LENZ) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
LENZ Therapeutics (NASDAQ:LENZ) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/12
05:45 am
lenz
Insider Spends US$239k Buying More Shares In LENZ Therapeutics [Yahoo! Finance]
Medium
Report
Insider Spends US$239k Buying More Shares In LENZ Therapeutics [Yahoo! Finance]
11/8
08:43 am
lenz
Analysts Are Upgrading LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Its Latest Results [Yahoo! Finance]
Low
Report
Analysts Are Upgrading LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Its Latest Results [Yahoo! Finance]
11/7
07:58 am
lenz
Growth Opportunities in the United States' $7+ Billion Ophthalmic Eye Droppers Market, 2025-2033 [Yahoo! Finance]
Low
Report
Growth Opportunities in the United States' $7+ Billion Ophthalmic Eye Droppers Market, 2025-2033 [Yahoo! Finance]
11/5
08:00 am
lenz
LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
High
Report
LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
10/29
08:00 am
lenz
LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
Medium
Report
LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025